Antibiotics

Marin H. Kollef, MD, discusses what to consider when calling for cultures.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

The broad-spectrum investigational antibiotic has been developed for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Superbugs resistant to colistin – a last-resort antibiotic – may have a new foe in octapeptins, antibiotics discovered decades ago that recently have been found to be effective against multidrug-resistant gram-negative bacteria.

The Cystic Fibrosis Foundation has awarded Motif Bio with $120,000 that will fund in vitro testing for the development of iclaprim to benefit patients with cystic fibrosis who have lung infections.

The FDA has approved Allergan's sNDA to expand the approved use of AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.

The World Health Organization (WHO) released its first report on antibiotic resistance surveillance data.

Historically, postoperative pulmonary complications have been the most common serious adverse event following upper abdominal surgery, with incidence rates ranging from 10% to 50%.

Dr. Richard Vickers, explains how ridinilazole affected the gut microbiome in participants of a phase 2 study.